|
NOD2
variant n (%)
|
24 (52%)
|
10 (32%)
|
p=0.10
|
|
One variant allele
|
17
|
5
|
p=0.061
|
|
Two variant alleles
|
7
|
5
|
p=0.75
|
|
Homozygous variant alleles
|
7
|
0
|
p=0.037*
|
|
Gender: female/male in %
|
45/55
|
48/52
|
p=0.89
|
|
Age: y
| | | |
|
mean/SD
|
25/12.8
|
24/13.9
|
p=0.62
|
|
median/interquartile range
|
21/17-30
|
19/15-29
|
p=0.29
|
|
average disease duration/SD
|
12.2/11.6
|
11.6/10.8
|
p=0.84
|
|
Age at diagnosis: y
| | | |
|
mean/SD
|
13/3.6
|
12/5.1
|
p=0.33
|
|
median/interquartile range
|
14/11-16
|
13/10-17
|
p=0.69
|
|
Localization: n (%)
| | | |
|
L1 ileal
|
8 (17%)
|
9 (29%)
|
p=0.27
|
|
L2 colonic
|
8 (17%)
|
6 (19%)
|
p=1.0
|
|
L3 ileocolonic
|
30 (65%)
|
16 (52%)
|
p=0.25
|
|
L4 isolated upper disease
|
0 (0%)
|
0 (0%)
|
p=1.0
|
|
Upper GI involvement
|
15 (33%)
|
13 (42%)
|
p=0.47
|
|
Behaviour: n (%)
| | | |
|
B1 non-stricturing/penetrating
|
27 (59%)
|
20 (65%)
|
p=0.64
|
|
B2 stricturing
|
11 (23%)
|
6 (19%)
|
p=0.78
|
|
B3 penetrating intern
|
6 (13%)
|
3 (10%)
|
p=0.73
|
|
B3p penetrating perianal
|
9 (19%)
|
3 (10%)
|
p=0.34
|
|
Underweight at diagnosis
|
14/27 (52%)
|
5/22 (32%)
|
p=0.0453*
|
|
Underweight in 1y follow-up
|
14 (30%)
|
2 (6%)
|
p=0.0113*
|
|
Short stature
|
5 (11%)
|
1 (3%)
|
p=0.39
|
|
Treatment: n (%)
| | | |
|
Steroid dependent/refractory
|
23 (50%)
|
9 (29%)
|
p=0.10
|
|
Azathioprine / MTX
|
35 (76%)
|
15 (48%)
|
p=0.016*
|
|
Anti-TNFα-antibody
|
20 (44%)
|
7 (26%)
|
p=0.09
|
